Blackstone Inc’s 4D Molecular Therapeutics FDMT Stock Holding History

Blackstone Inc’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50,000	Closed	-$904K	–	157
2023 Q2	$904K	Buy	+50,000	New	+$921K	﹤0.01%	128

Other funds holding FDMT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Blackstone Inc's FDMT Position: Q3 2023 in Review

Blackstone Inc sold out of 4D Molecular Therapeutics (FDMT) in Q3 2023, closing a stake of 50,000 shares — an estimated $904K sold.

Blackstone Inc first reported a position in FDMT in Q2 2023 and held it in 1 quarter. The position peaked at $904K in Q2 2023. 110 funds tracked by Wall St. Rank hold FDMT as of Q3 2023.

Blackstone Inc reported no remaining 4D Molecular Therapeutics position as of Q3 2023 after selling out during the quarter.
Blackstone Inc sold 50,000 4D Molecular Therapeutics shares in Q3 2023, an estimated $904K.
Blackstone Inc first reported a position in 4D Molecular Therapeutics in Q2 2023 and held it in 1 quarter.
Blackstone Inc's 4D Molecular Therapeutics position peaked at $904K in Q2 2023.
110 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2023.

Based on Blackstone Inc's 13F filing for Q3 2023, filed 14 Nov 2023.